Hester to develop low pathogenic avian influenza inactivated vaccine for poultry
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
For anaemia control in children (0-19 years) & resolves for Call to Action in this direction
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
The cash and debt free consideration value is €370 million.
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
J. B. Chemicals & Pharmaceuticals has informed that the acquisition of the Razel franchise from Glenmark Pharmaceuticals Limited has been successfully completed.
Subscribe To Our Newsletter & Stay Updated